At the archive date, BECTON DICKINSON & CO was expected to release its Q3 2026 10-Q filing on November 2, 2026, after market close. Last quarter: BD's Q3 FY2026 saw solid revenue growth offset by margin pressure from tariffs and restructuring, while the company completed its Life Sciences spin-off and returned significant capital to shareholders.
EPS Estimate
$4.11
Revenue Estimate
$5.17B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the BDX page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Management noted that tariffs have adversely impacted operating expense in Q3 and expects a continued adverse impact for fiscal year 2026 and potentially beyond, primarily from imports with no exemption opportunities. Mitigation efforts include sourcing optimization and tariff exemption claims, though the collectability of related receivables is uncertain.
During the nine months ended June 30, 2026, BD recorded a $450 million non-cash asset impairment charge as part of restructuring costs. This charge stemmed from the commitment to exit certain operational activities and projects that no longer align with the new 'Excellence Unleashed' strategy.
Worldwide revenue increased 5.4%, composed of 4.1% volume/other, 0.3% pricing, and 1.0% foreign currency translation. All four segments grew, with Interventional up 6.4% and BioPharma Systems up 6.6% on strength in oncology, GLP-1 delivery, and infection prevention products.
Revenue
$4.98B
+5.44% YoY
EPS (Diluted)
$1.37
-31.50% YoY
Operating Income
$663M
-10.28% YoY
Add BDX to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.